Literature DB >> 24649345

Identification of differences in immunotherapy knowledge and practice patterns among oncologists from six European countries.

Ivan Marques Borrello1, Madeline Mag Schaffer2, Elena Roehrl2, Jessica Falco Marshall3.   

Abstract

The treatment of cancer has changed significantly over the past decade, from a treatment paradigm based primarily on surgery, chemotherapy and radiotherapy, to the development of targeted therapies involving tumor-specific signaling pathways, as well as the immune system. Recent developments have demonstrated the significant clinical benefits of immunotherapy that are quickly being established as standard treatments for certain malignancies. In this study, we demonstrated that clinical practice is not keeping pace with advancing immuno-oncology principles and research. We further demonstrated that the incorporation of immunotherapeutic approaches into the treatment of cancer patients varies widely, not only between developed and developing countries, but also between countries in specific geographical areas that have experienced similar cultural and economic development. We developed a survey to assess the deficiencies in scientific understanding, access to information and treatment options and investigated the differences in clinical practice behaviors among oncologists from six European countries: France, Germany, Greece, Italy, Spain and the United Kingdom. Our data demonstrated significant differences in all the categories assessed. Therefore, we concluded that there is a need to develop similar assessment tools to identify care imbalances, so that initiatives may be developed to correct care inequities that ultimately affect patient outcomes worldwide.

Entities:  

Keywords:  cancer immunotherapy; cancer vaccines; monoclonal antibodies

Year:  2014        PMID: 24649345      PMCID: PMC3917767          DOI: 10.3892/mco.2014.242

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  10 in total

1.  Two hundred years of cancer research.

Authors:  Vincent T DeVita; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2012-05-30       Impact factor: 91.245

2.  Medical oncology: the long-awaited prize of recognition.

Authors:  P G Casali
Journal:  Ann Oncol       Date:  2011-06-30       Impact factor: 32.976

Review 3.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

Review 4.  Immunotherapy of cancer.

Authors:  Hossein Borghaei; Mitchell R Smith; Kerry S Campbell
Journal:  Eur J Pharmacol       Date:  2009-10-20       Impact factor: 4.432

5.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors:  Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

6.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

Review 7.  Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.

Authors:  O J Finn
Journal:  Ann Oncol       Date:  2012-09       Impact factor: 32.976

Review 8.  Approved monoclonal antibodies for cancer therapy.

Authors:  Michael Boyiadzis; Kenneth A Foon
Journal:  Expert Opin Biol Ther       Date:  2008-08       Impact factor: 4.388

9.  Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force.

Authors:  Lisa H Butterfield; Mary L Disis; Samir N Khleif; James M Balwit; Francesco M Marincola
Journal:  J Transl Med       Date:  2010-12-07       Impact factor: 5.531

10.  The immuno-oncology framework: Enabling a new era of cancer therapy.

Authors:  Axel Hoos; Cedrik Britten
Journal:  Oncoimmunology       Date:  2012-05-01       Impact factor: 8.110

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.